A Combination of Low-Dose Systemic Etretinate and Topical Calcipotriol/Betamethasone Dipropionate Treatment for Hyperkeratosis and Itching in Olmsted Syndrome Associated with a TRPV3 Mutation

    May 2017 in “ Journal of dermatological science ”
    Takuya Takeichi, Katsuhiko Tsukamoto, Yusuke Okuno … Masashi Akiyama
    Studysummary This study reviewed the genetic and phenotypic aspects of Olmsted syndrome, highlighting pathogenic mutations in TRPV3 and MBTPS2 genes and their association with specific skin manifestations like symmetrical keratoderma and hyperkeratotic plaques.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jdsjournal.com →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Two Familial Cases of Olmsted-Like Syndrome with a G573V Mutation of the TRPV3 Gene Clinical and experimental dermatology · 2016
    2. Expanding The Phenotypic Spectrum Of Olmsted Syndrome Journal of Investigative Dermatology · 2015